Case number 1:17-cv-01862
Glaxo Group Ltd. et al v. Aurobindo Pharma USA, Inc. et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Feb 6, 2018 | 7 | Patent/Trademark Report to Commissioner (1) |
| Feb 6, 2018 | N/A | Terminated Case (0) Docket Text: CASE CLOSED (lih) |
| Feb 6, 2018 | 7 | Notice of dismissal (1) |
| Feb 6, 2018 | 7 | Main Document (1) Docket Text: Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 8,637,512 B2; US 9,144,547 B2. (Attachments: # (1) Notice of dismissal)(lih) |
| Feb 2, 2018 | 6 | Notice of Voluntary Dismissal (1) Docket Text: NOTICE of Voluntary Dismissal by Glaxo Group Ltd., GlaxoSmithKline LLC (Farnan, Brian) |
| Jan 10, 2018 | N/A | Remark (0) Docket Text: **NOTE: If the parties jointly consent to Magistrate Judge Fallons jurisdiction to conduct all proceedings in this case, then the Pretrial Conference and Trial will be presided over by Judge Fallon consistent with 28 U.S.C. ยง 636. Otherwise, in accordance with the District Court's procedures for "Assignment of Cases to Visiting Judges" (issued May 26, 2017 and available on the District Court's website), upon the filing of a case-dispositive motion (e.g., a motion to dismiss, a motion for judgment on the pleadings, a motion for summary judgment, or initiation of the claim construction process in a patent case), VAC cases will be reassigned to a visiting District Judge, and any further dates in the Scheduling Order, including the Pretrial Conference and Trial dates, may be adjusted dependent on the availability of the visiting District Judge.** (lih) |
| Jan 3, 2018 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Assigned to Vacant Judgeship (2017). Please include initials of VAC after the case number on all documents filed. (rjb) |
| Jan 3, 2018 | N/A | Case Referred to Magistrate Judge (0) Docket Text: CASE REFERRED to Magistrate Judge Sherry R. Fallon. (This matter has been assigned to the Vacant Judgeship and referred to a Magistrate Judge for handling through case-dispositive motions. The Magistrate Judge has full authority permitted by law to manage this matter, including entering schedules through trial, deciding non-dispositive matters and making recommendations as to the resolution of dispositive matters. Litigants and counsel are reminded that they have the option of consenting to the Magistrate Judge to handle the case in full, including trial, or consenting to having a particular motion resolved by the Magistrate Judge.) (rjb) |
| Dec 27, 2017 | 1 | Complaint (11) |
| Dec 27, 2017 | N/A | Summons Issued (0) Docket Text: Summons Issued with Magistrate Consent Notice attached as to Aurobindo Pharma USA, Inc. on 12/27/2017. Requesting party or attorney should pick up issued summons at the Help Desk, Room 4209, or call 302-573-6170 and ask the Clerk to mail the summons to them. (nmg) |
| Dec 27, 2017 | 1 | Exhibit A (30) |
| Dec 27, 2017 | 1 | Exhibit B (10) |
| Dec 27, 2017 | 1 | Civil Cover Sheet (1) |
| Dec 27, 2017 | 2 | Magistrate Consent Forms (3) Docket Text: Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (nmg) |
| Dec 27, 2017 | 3 | ANDA Form (2) Docket Text: Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 11/14/2017. Date of Expiration of Patent: See Attached.Thirty Month Stay Deadline: 5/14/2020. (nmg) |
| Dec 27, 2017 | 4 | Patent/Trademark Report to Commissioner (1) Docket Text: Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 8,637,512 B2; US 9,144,547 B2. (nmg) |
| Dec 27, 2017 | 5 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent GlaxoSmithKline plc. for Glaxo Group Ltd., GlaxoSmithKline LLC filed by Glaxo Group Ltd., GlaxoSmithKline LLC. (nmg) |
| Dec 27, 2017 | 1 | Main Document (11) Docket Text: COMPLAINT for PATENT INFRINGEMENT filed against Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-2291379.) - filed by GlaxoSmithKline LLC, Glaxo Group Ltd.. (Attachments: # (1) Exhibit A, # (2) Exhibit B, # (3) Civil Cover Sheet)(nmg) |
| Dec 27, 2017 | 1 | Complaint* (1) |
